focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInsig Ai Plc Regulatory News (INSG)

Share Price Information for Insig Ai Plc (INSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.25
Bid: 12.50
Ask: 14.00
Change: 0.50 (3.92%)
Spread: 1.50 (12.00%)
Open: 13.25
High: 13.25
Low: 13.25
Prev. Close: 12.75
INSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Funding facility, share allotment & PDMR dealing

4 Apr 2024 07:00

RNS Number : 2330J
Insig AI Plc
04 April 2024
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) NO. 596/2014. It forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this information is considered to be in the public domain.

 

Insig AI plc

("Insig AI" or the "Company")

Funding facility, share allotment and director dealing

Insig AI plc (AIM: INSG), the data science and machine learning group, announces that the Company has formally agreed to a £250,000 equity funding facility (the "Funding Facility") with Richard Bernstein, Executive Chairman of Insig AI. The Funding Facility will allow Mr Bernstein to subscribe for up to 1,250,000 new ordinary shares at 20 pence per share until 31 August 2024. This follows the proposed facility as set out in the Company's 'Trading update and equity funding facility proposal' announced on 2 April 2024.

Share Allotment

Pursuant to the Funding Facility, Richard Bernstein has subscribed for 250,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 20 pence per share raising gross proceeds of £50,000 (the "Subscription Shares"). The subscription price of 20 pence per share represents a 17.6% premium to the closing share price of 17 pence on 3 April 2024.  Following the issuance of the Subscription Shares, Mr Bernstein's shareholding is 20,605,380 Ordinary Shares, which represents 18.8% of the Company's total voting rights. After the issuance of the Subscription Shares, £200,000 remains available for draw down under the Funding Facility.

Related Party Transaction

The Funding Facility, entered into by Richard Bernstein, a director of the Company constitutes a related party transaction under the AIM Rules.

The directors of the Company (excluding Richard Bernstein), having consulted with Zeus Capital Limited, the Company's nominated adviser, consider that the terms of the Funding Facility, are fair and reasonable insofar as the Company's shareholders are concerned.

Admission and Total Voting Rights

 

Application will be made to the London Stock Exchange for admission of the Subscription Shares to trading on AIM ("Admission"). It is expected that Admission will become effective and dealings in the Subscription Shares will commence on or around 9 April 2024.

 

The Subscription Shares will be issued fully paid and will rank pari passu in all respects with the Company's existing Ordinary Shares.

 

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 109,851,025. As the Company currently holds 505,888 Ordinary Shares in treasury, the total number of voting rights in the Company following Admission will be is 109,345,137. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for Companies issued by the London Stock Exchange plc as amended from time to time.

 

For further information, please visit www.insg.ai or contact:

 

 

Insig AI plc

Richard Bernstein

Colm McVeigh, CEO 

richard.bernstein@insg.ai

colin.mcveigh@insg.ai 

 

Zeus (Nominated Adviser & Broker)

David Foreman / James Hornigold 

+44 (0) 203 829 5000

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Richard Bernstein

2.

Reason for the notification

a)

Position/status:

Director

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Insig AI Plc

b)

LEI:

21380098CKBAG1NWCD98

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence

GB00BYV31355

b)

Nature of the transaction:

Issue of ordinary shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

20 pence

250,000

 

d)

Aggregated information:

Aggregated volume:

Price:

Single transaction as in 4 c) above

Price(s)

Volume(s)

20 pence

250,000

 

e)

Date of the transaction:

3 April 2024

 

f)

Place of the transaction:

Off-market

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEIJMRTMTJMBPI
12
Date   Source Headline
2nd May 20247:00 amRNSShare subscription, director dealing and TVR
17th Apr 20247:00 amRNSDirector/PDMR Shareholding
4th Apr 20247:00 amRNSFunding facility, share allotment & PDMR dealing
2nd Apr 20247:00 amRNSTrading update & equity funding facility proposal
28th Dec 20237:00 amRNSInclusion within UN Environment Programme Tool
22nd Dec 20237:00 amRNSDirector/PDMR Shareholding
21st Dec 20237:00 amRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSInterim results
28th Nov 20237:00 amRNSAppointment of investor relations adviser and TVR
27th Nov 20237:00 amRNSCorporate development adviser and TVR
15th Nov 20237:00 amRNSDisposal, Loan Conversion, New Project Win & TVR
30th Oct 20237:00 amRNSNew Product Launch
28th Sep 20237:00 amRNSAppointment of Strategic Adviser and TVR
15th Sep 20233:56 pmRNSResult of AGM
15th Sep 20237:00 amRNSAGM Statement
30th Aug 20237:00 amRNSDirector/PDMR Shareholding
24th Aug 20237:00 amRNSDirector/PDMR Shareholding
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSFinal Results, Posting of Report and Notice of AGM
1st Aug 20234:42 pmRNSChange of Registered Office
31st Jul 20235:30 pmRNSTotal Voting Rights
4th Jul 20237:00 amRNSRevision of Convertible Loan Facility Agreement
19th May 20237:00 amRNSDirector/PDMR Shareholding
11th May 20237:00 amRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Apr 20237:00 amRNSDeath of Director
24th Apr 20237:02 amRNSEquity subscription
24th Apr 20237:01 amRNSInsig AI Data & Technology Collaboration with FCA
24th Apr 20237:00 amRNSTrading and operations update
9th Mar 20237:00 amRNSInsig AI showcase Generative AI Product Capability
6th Feb 20237:00 amRNSGenerative AI Product Capability
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
9th Jan 20237:00 amRNSConvertible Loan Facility Drawdown
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20227:00 amRNSDirector Dealing
22nd Dec 20227:00 amRNSRevision of Convertible Loan Facility Agreements
21st Dec 20227:00 amRNSDirectors gift shares to Company treasury & TVR
19th Dec 20227:00 amRNSInterim Results
8th Nov 20227:00 amRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSNew Contract Win
3rd Nov 20227:00 amRNSTrading update
26th Oct 20227:00 amRNSConvertible Loan Facility drawdown
17th Oct 20227:00 amRNSPartnership agreement with BRAIN
12th Oct 20227:00 amRNSConvertible Loan Facility Agreement and drawdown
30th Sep 202212:13 pmRNSResult of Annual General Meeting & General Meeting
30th Sep 20227:00 amRNSContract win
26th Sep 20227:00 amRNSConvertible Loan Facility drawdown
20th Sep 20227:00 amRNSChange of Registered Office
12th Sep 20227:00 amRNSConvertible Loan Facility Agreement
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.